Patents Assigned to Inex Pharmaceuticals Corporation
-
Publication number: 20040009944Abstract: The invention discloses that methylated nucleic acids, particularly methylated oligonucleotides, and more particularly methylated oligonucleotides bearing a methylated cytosine of a CpG dinucleotide motif can be made immunostimulatory in vivo, by encapsulation of the nucleic acid in a lipid particle. It is further disclosed that encapsulated methylated nucleic acids that are ordinarily not immunostimulatory in vivo are as effective or even more effective than their encapsulated unmethylated counterparts. Also disclosed are methods for activating and/or expanding dendritic cell populations in response to antigenic stimulation using the compositions and methods disclosed herein.Type: ApplicationFiled: May 12, 2003Publication date: January 15, 2004Applicant: Inex Pharmaceuticals CorporationInventors: Ying Kee Tam, Sean C. Semple, Sandra K. Klimuk, Ghania Chikh
-
Patent number: 6586559Abstract: The present invention relates to new polyamide oligomers. These oligomers can be conjugated to lipids, nucleic acids, peptides, proteins, etc. The oligomer-lipid conjugates can be used to form liposomes, virusomes, micelles, etc., optionally containing drugs or biological agents. The polyamide oligomers are heterobifunctional allowing the attachment of other suitable ligand compounds (e.g., a targeting moiety). In addition, methods of use for the liposomes, virusomes, micelles, etc., are provided.Type: GrantFiled: August 30, 2001Date of Patent: July 1, 2003Assignee: Inex Pharmaceuticals CorporationInventor: Steven Michial Ansell
-
Patent number: 6586410Abstract: Novel lipid-nucleic acid particulate complexes which are useful for in vitro or in vivo gene transfer are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. Upon removal of a solubilizing component (i.e., detergent or an organic solvent) the lipid-nucleic acid complexes form particles wherein the nucleic acid is serum-stable and is protected from degradation. The particles thus formed have access to extravascular sites and target cell populations and are suitable for the therapeutic delivery of nucleic acids.Type: GrantFiled: May 8, 2000Date of Patent: July 1, 2003Assignee: Inex Pharmaceuticals CorporationInventors: Jeffery J. Wheeler, Marcel B. Bally, Yuan-Peng Zhang, Dorothy L. Reimer, Michael Hope, Pieter R. Cullis, Peter Scherrer
-
Publication number: 20030082228Abstract: The present invention provides methods and compositions for the treatment and prevention of any of a large number of diseases and conditions with an angiogenic component, e.g., cancer. The present invention is based upon the discovery that liposome-encapsulated chemotherapeutic agents, such as alkaloids (e.g., vinca alkaloids such as vincristine), are surprisingly effective at treating such diseases or conditions when administered at a higher frequency than those used with conventional administration strategies. Such methods can be used to treat diseases such as cancer even when the cancer comprises cells that are resistant to the chemotherapeutic alkaloid. The liposome encapsulation of the chemotherapeutic agents, e.g., alkaloids, imparts dramatic improvements in the stability, biodistribution, and delivery of the agents, thereby allowing more efficacious and convenient administration to a patient with any of the herein-described diseases or conditions.Type: ApplicationFiled: May 9, 2002Publication date: May 1, 2003Applicant: Inex Pharmaceuticals CorporationInventors: Clay Flowers, David Saltman, Patrick M.S. Tam, Clive T.R. Burge, Troy O. Hasrasym
-
Publication number: 20020119990Abstract: This invention relates to improved liposomal camptothecin compositions and methods of manufacturing and using such compositions for treating neoplasia and for inhibiting angiogenesis.Type: ApplicationFiled: June 29, 2001Publication date: August 29, 2002Applicant: Inex Pharmaceuticals CorporationInventors: Thomas D. Madden, Sean C. Semple
-
Publication number: 20020110586Abstract: This invention relates to liposomal antineoplastic agents (e.g., camptothecin) compositions and methods of using such compositions for treating neoplasia and for inhibiting angiogenesis. The compositions and methods are useful for modulating the plasma circulation half-life of an active agent.Type: ApplicationFiled: June 29, 2001Publication date: August 15, 2002Applicant: Inex Pharmaceuticals CorporationInventors: Thomas D. Madden, Sean C. Semple, Quet F. Ahkong
-
Patent number: 5814335Abstract: Liposomal formulations having extended circulation time in vivo and increased drug retention are comprised of sphingomyelin and cholesterol and have an acidic intraliposomal pH. The formulations have enhanced stability and thus are used in methods which provide improved drug delivery and more effective treatment. The delivery of ciprofloxacin, and alkaloid drugs, particularly swainsonine, vincristine and vinblastine, is significantly improved.Type: GrantFiled: September 17, 1997Date of Patent: September 29, 1998Assignee: Inex Pharmaceuticals CorporationInventors: Murray S. Webb, Marcel B. Bally, Lawrence D. Mayer, James J. Miller, Paul G. Tardi
-
Patent number: 5753613Abstract: The present invention provides compositions and methods which are useful for the introduction of polyanionic materials into cells. The compositions are mixtures of cationic compounds and neutral lipids which are typically formulated as liposomes. The cationic compounds are quaternary ammonium compounds wherein the nitrogen has two attached long chain alkyl groups, at least one of which is unsaturated. The methods for transfecting cells involve (a) contacting the polyanionic materials with the compositions above to form a polyanionic material-liposome complex, and (b) contacting the complex with the cells to be transfected.Type: GrantFiled: May 16, 1995Date of Patent: May 19, 1998Assignee: Inex Pharmaceuticals CorporationInventors: Steven Michial Ansell, Barbara Mui, Michael Hope
-
Patent number: 5741516Abstract: Liposomal formulations having extended circulation time in vivo and increased drug retention are comprised of sphingomyelin and cholesterol and have an acidic intraliposomal pH. The formulations have enhanced stability and thus are used in methods which provide improved drug delivery and more effective treatment. The delivery of ciprofloxacin, and alkaloid drugs, particularly swainsonine, vincristine and vinblastine, is significantly improved.Type: GrantFiled: December 14, 1995Date of Patent: April 21, 1998Assignee: Inex Pharmaceuticals CorporationInventors: Murray S. Webb, Marcel B. Bally, Lawrence D. Mayer, James J. Miller, Paul G. Tardi
-
Patent number: 5705385Abstract: Novel, hydrophobic lipid-nucleic acid complexes. The complexes are charge-neutralized and contain the nucleic acid in a non-condensed form. Manipulation of these complexes in either detergent-based or organic solvent-based systems leads to particle formation. Thus, the present invention also provides methods of preparing lipid-nucleic acid particles which are useful for the therapeutic delivery of nucleic acids. The particles are constructed via hydrophobic lipid-nucleic acid intermediates (or complexes). Upon removal of a solubilizing component (i.e., detergent or an organic solvent) the nucleic acid forms a particle with lipids and is protected from degradation. The particles thus formed are suitable for use in intravenous nucleic acid transfer as they are stable in circulation, of a size required for pharmacodynamic behavior resulting in access to extravascular sites and target cell populations.Type: GrantFiled: June 7, 1995Date of Patent: January 6, 1998Assignee: Inex Pharmaceuticals CorporationInventors: Marcel B. Bally, Yuan-Peng Zhang, Dorothy L. Reimer, Jeffery J. Wheeler
-
Patent number: 5595756Abstract: Liposomal compositions encapsulating bioactive agents and having improved circulation longevity of the agents are disclosed. Such liposomes combine a low pH of the solution in which a bioactive agent is entrapped and a sugar-modified lipid or an amine-bearing lipid, the combination of which enhances the retention of the encapsulated bioactive agent and thereby promotes circulation longevity. The present invention also discloses methods of making and using such compositions.Type: GrantFiled: December 22, 1993Date of Patent: January 21, 1997Assignees: Inex Pharmaceuticals Corporation, University of British of ColumbiaInventors: Marcel B. Bally, Nancy L. Boman, Pieter R. Cullis, Lawrence D. Mayer
-
Patent number: 5543152Abstract: Liposomal formulations having extended circulation time in vivo and increased drug retention are comprised of sphingomyelin and cholesterol and have an acidic intraliposomal pH. The formulations have enhanced stability and thus are used in methods which provide improved drug delivery and more effective treatment. The delivery of lipophilic drugs such as the vinca alkaloids, and particularly vincristine and vinblastine, to tumors is significantly improved.Type: GrantFiled: June 20, 1994Date of Patent: August 6, 1996Assignee: Inex Pharmaceuticals CorporationInventors: Murray S. Webb, Marcel B. Bally, Lawrence D. Mayer